Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy

被引:32
|
作者
Trestini, Ilaria [1 ]
Carbognin, Luisa [1 ]
Sperduti, Isabella [2 ]
Bonaiuto, Clelia [1 ]
Auriemma, Alessandra [1 ]
Melisi, Davide [1 ]
Salvatore, Lisa [1 ]
Bria, Emilio [1 ]
Tortora, Giampaolo [1 ]
机构
[1] Univ Verona, Azienda Osped Univ Integrata, UOC Oncol, Verona, Italy
[2] Regina Elena Inst Canc Res, Dept Biostat, Rome, Italy
关键词
ENERGY-EXPENDITURE; CACHECTIC PATIENTS; CANCER CACHEXIA; MALNUTRITION; STRATEGIES; MANAGEMENT; OUTCOMES;
D O I
10.1038/s41430-018-0155-5
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/objectives The aim of this analysis was to determine the risk of malnutrition and the prognostic value of nutritional intervention in patients affected by pancreatic ductal adenocarcinoma (PDAC) undergoing chemotherapy. Subjects/methods Clinical-pathological and nutritional data were correlated with overall survival (OS) using a Cox model. Nutritional status was determined by Malnutrition Universal Screening Tool (MUST), body mass index, weight loss in the past 6 months, presence of nutrition-related symptoms, and current energy intake. Nutritional intervention included appropriate individual dietary counseling. Results Data from 109 patients were gathered (median age 63 years). The majority of patients (64.2%) presented a MUST value of >= 2, corresponding to a high risk of malnutrition. At multivariate analysis for OS in locally advanced and metastatic PDAC patients, the time between the diagnosis and the nutritional intervention (HR 2.22, p = 0.017), the performance status (HR 1.38, p = 0.075), the surgery of the primary (HR 5.89, p = 0.005), and the response to the first line (HR 5.9, p = 0.03) were independent significant predictors of outcome. Furthermore, a weight gain > 2% from the baseline weight was correlated with the time between the diagnosis and the nutritional intervention (p = 0.021): in patients receiving a nutritional support within 3 months from diagnosis, a 2% weight gain was associated with a 2-year OS benefit (50.3% vs. 33.0%, p = 0.04). Conclusions This analysis suggests that the early nutritional support may contribute to influence the prognosis of patients affected by advanced PDAC undergoing chemotherapy.
引用
收藏
页码:772 / 779
页数:8
相关论文
共 50 条
  • [31] The Impact of Nutritional Support on Survival Outcomes in Patients with Advanced Gastric Adenocarcinoma Treated with Chemotherapy
    Sugiyama, Keiji
    Shiraishi, Kazuhiro
    Motohashi, Takuya
    Onoda, Shinpei
    Sato, Mariko
    Kato, Kyoko
    Uda, Hiroaki
    Hattori, Masashi
    Suenaga, Masaya
    Hirashima, Noboru
    Shimada, Masaaki
    Kataoka, Masato
    Kitagawa, Chiyoe
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2023, 75 (03): : 867 - 875
  • [32] Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients
    Xiao, Yuanyuan
    Chen, Wen
    Xie, Zhihui
    Shao, Zhenyi
    Xie, Hua
    Qin, Guoyou
    Zhao, Naiqing
    BMC CANCER, 2017, 17
  • [33] Comparison of Prognostic Markers for Patients' Prognosis in Advanced Pancreatic Ductal Adenocarcinoma
    Suzuki, Rei
    Takagi, Tadayuki
    Hikichi, Takuto
    Watanabe, Ko
    Sugimoto, Mitsuru
    Waragai, Yuichi
    Kikuchi, Hitomi
    Asama, Hiroyuki
    Takasumi, Mika
    Ohira, Hiromasa
    GASTROENTEROLOGY, 2016, 150 (04) : S324 - S324
  • [34] Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients
    Yuanyuan Xiao
    Wen Chen
    Zhihui Xie
    Zhenyi Shao
    Hua Xie
    Guoyou Qin
    Naiqing Zhao
    BMC Cancer, 17
  • [35] Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma
    Abe, Toshiya
    Nakata, Kohei
    Kibe, Shin
    Mori, Yasuhisa
    Miyasaka, Yoshihiro
    Ohuchida, Kenoki
    Ohtsuka, Takao
    Oda, Yoshinao
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (13) : 3996 - 4003
  • [36] Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma
    Toshiya Abe
    Kohei Nakata
    Shin Kibe
    Yasuhisa Mori
    Yoshihiro Miyasaka
    Kenoki Ohuchida
    Takao Ohtsuka
    Yoshinao Oda
    Masafumi Nakamura
    Annals of Surgical Oncology, 2018, 25 : 3996 - 4003
  • [37] FOLFIRINOX FOR LOCALLY ADVANCED OR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDA); CLINICAL OUTCOMES AND PROGNOSTIC FACTORS, THE ROYAL MARSDEN (RM) EXPERIENCE
    Yu, Moorcraft Sing
    Khurum, Khan
    Clare, Peckitt
    David, Watkins
    Sheela, Rao
    David, Cunningham
    Ian, Chau
    ANNALS OF ONCOLOGY, 2014, 25 : 78 - 78
  • [38] Platinum-based chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): summary of evidence and application in clinical practice
    Reinacher-Schick, Anke
    Arnold, Dirk
    Venerito, Marino
    Goekkurt, Eray
    Kraeft, Anna-Lena
    Seufferlein, Thomas
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (12) : 752 - 763
  • [39] Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection
    Ren, Weizheng
    Xourafas, Dimitrios
    Ashley, Stanley W.
    Clancy, Thomas E.
    AMERICAN SURGEON, 2022, 88 (06) : 1172 - 1180
  • [40] Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma
    Bullock, Andrea
    Stuart, Keith
    Jacobus, Susanna
    Abrams, Thomas
    Wadlow, Raymond
    Goldstein, Michael
    Miksad, Rebecca
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (06) : 945 - +